Stockscreener 앱 받기
6.79
2.44%
-0.17
전일 마감가:
$6.96
열려 있는:
$6.95
하루 거래량:
2.10M
Relative Volume:
1.67
시가총액:
$464.28M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-1.3083
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
+0.00%
1개월 성능:
-8.86%
6개월 성능:
-37.96%
1년 성능:
-9.35%
1일 변동 폭
$6.35
$6.9783
1주일 범위
$6.35
$7.20
52주 변동 폭
$6.065
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
6.79 | 464.28M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Sold by Jane Street Group LLC - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.9%Here's What Happened - MarketBeat
Barclays PLC Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Geode Capital Management LLC Buys 56,871 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% HigherWhat's Next? - MarketBeat
State Street Corp Raises Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
State Street Corp Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 By Investing.com - Investing.com South Africa
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2%Here's Why - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Recovers 28.94% From Low: Are We There Yet? - Stocks Register
Helicobacter pylori Infection Market to Show Remarkable Growth - openPR
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying Activity - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock By Investing.com - Investing.com Australia
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock - Investing.com India
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock By Investing.com - Investing.com South Africa
How To Trade (PHAT) - Stock Traders Daily
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Frank Karbe Increases Stake in Phathom Pharmaceuticals Inc (PHAT) - GuruFocus.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying Activity - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $99,125.00 in Stock - MarketBeat
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock - Investing.com
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value - Simply Wall St
Charles Schwab Investment Management Inc. Purchases 6,990 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Phathom Pharma shares stay Buy rated on extended vonoprazan exclusivity to 2032 - Investing.com Canada
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? - MSN
Phathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity - Investing.com
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity By Investing.com - Investing.com UK
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - The Manila Times
Phathom Pharmaceuticals Submits Citizen Petition to FDA - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):